Northwest Biotherapeutics Launches Public Information Campaign in Collaboration with the Money Channel

BETHESDA, Md., March 29, 2011 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO) announced today that it has entered into a collaboration with The Money Channel to increase public and investor awareness of the advantages of immunotherapy for cancer generally, and the potential of NWBT's DCVax® immunotherapy in particular.  

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

This public awareness program will involve an ongoing national media campaign through radio and television, including appearances on the daily radio program "AMERICAN SCENE" with Steve Crowley, which reaches audiences nationwide, and appearances on the weekly national television program "WALLSTREETCAST" which airs on the FOX Business Network.  NWBT's Chairman, Ms. Linda Powers, will be the on-air guest on behalf of NWBT.

"We are extremely pleased to work with the MONEY CHANNEL, which has a strong track record of identifying important new technologies and investment opportunities, and is a highly respected channel that reaches audiences throughout the country," said NWBT's Chairman, Linda Powers. "Together, we will help raise public and investor awareness about the exciting potential of immunotherapies for cancer, and about the striking and consistent results obtained in clinical trials to date with NWBT's DCVax immunotherapies for brain and prostate cancer."

About Northwest:

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis.  The Company has a broad platform technology, with multiple product applications, involving dendritic cell-based therapeutic vaccines to treat cancer.  The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal form of brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers.  For further information about clinical sites and about the Company, please visit the Company's web site at www.nwbio.com.

About the Money Channel Inc:

The Money Channel Inc. is headquartered in Coconut Creek, Florida and has operated as a Media Company since 2004.  The Money Channel's CEO, Stephen Crowley, is a former PriceWaterhouse and Co. CPA-Manager, the former Money Editor of ABC's "Good Morning America," as well as the author of "MONEY FOR LIFE" published by Simon & Schuster. Mr. Crowley and his team have produced more than 12,000 national Radio and Television programs since 1982 in markets ranging across the USA.

"American Scene" Radio is co-branded with "Investors Business Daily," is broadcast via www.investors.com/americanscene, and is also associated with "thestreet.com" founded by Jim Cramer.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax®-Brain and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

SOURCE Northwest Biotherapeutics, Inc.